

15 January 2026

Vitrafy Enters Strategic Commercial Agreement with IMV Technologies

Key Highlights

- Vitrafy has entered into a 12-month exclusive Agreement with global animal reproduction leader, IMV Technologies.
- IMV, a French based multi-national conglomerate, is a global market leader with over 500 million animal inseminations annually.
- The partnership is designed to integrate Vitrafy's next-generation cryopreservation technology with IMV's globally recognised offering.
- During the term, monthly revenues will be generated with further milestone payments ahead of an anticipated long-term agreement.
- The partnership aims to jointly commercialise a global cryopreservation offering for farm animals and aquaculture.

Upon execution of the Agreement, Managing Director and CEO, **Brent Owens**, commented: *"This agreement with IMV Technologies represents a significant step in Vitrafy's commercialisation strategy. By partnering with the global leader in animal reproduction, we accelerate the validation and adoption of our cryopreservation technology at scale."*

This Agreement creates immediate revenue opportunities but also positions Vitrafy for long-term growth through global market access, while we continue to advance our human health strategy in North America."

CEO of IMV Technologies, **Oliver Kohlhaas**, commented: *"Vitrafy's unique nitrogen-free cryopreservation technology has the potential to improve post-thaw cell viability. We are excited to collaborate with Vitrafy to offer even better solutions for our customers."*

Overview

Vitrafy Life Sciences Limited (ASX: **VFY**) ("**Vitrafy**" or "**the Company**") announces that it has entered into a Collaboration and Development Agreement ("**CDA**" or "**the Agreement**") with IMV Technologies, SA ("**IMV**").

This Agreement establishes a 12-month strategic collaboration to co-develop a market-ready solution that brings together the strengths of both organisations - expertise, product portfolios and scientific innovation - to establish a new benchmark in reproductive cryopreservation across farm animals, and aquaculture.

Upon the successful completion of the program of work under this Agreement, it is anticipated that a long-term commercial agreement between Vitrafy and IMV will be executed. A long-term commercial agreement would enable IMV to deliver Vitrafy's state of the art reproductive



cryopreservation service offering to the farm animal market, accelerating adoption within the highly concentrated, global animal market.

By partnering with the global leader for animal reproduction, Vitrafy is executing on its stated strategy of accelerating commercial scale in the unregulated animal reproduction market. Global scale achieved via the partnership will allow Vitrafy to continue to focus resources on the expansion efforts for the human health market in North America.

Background to IMV

IMV is a global leader in animal reproductive technologies, specialising in advanced products and services that support artificial insemination, cryopreservation and reproductive management across farm animals, aquaculture and companion animals.

With decades of experience commercialising innovative products; a broad, complementary product portfolio; and a strong global footprint; IMV plays a significant role in improving breeding efficiency, genetic progress and animal welfare across the agriculture and veterinary sectors.

Founded in 1963, IMV is recognised as the global leader in providing products and services that support the artificial insemination of animals. With an international footprint (that spans 128 countries) and a comprehensive product portfolio, IMV's products and services support more than half a billion inseminations each year—equating to approximately 1 insemination every 7 seconds using an IMV product.

Terms of the Agreement

The Agreement establishes an initial 12-month term, during which Vitrafy and IMV will complete validation and in-field commercial runs of Vitrafy's cryopreservation technology (hardware and software) across a range of species, whilst developing a commercialisation strategy to take the offering to the global market.

Both parties will contribute resources to ensure a successful process. Vitrafy will be paid a monthly fee for the 12-month term of the Agreement of up-to A\$480,000, plus Vitrafy has the ability to secure milestone payments for the successful achievement of pre-determined milestones of A\$450,000. Both parties have the ability to extend the Agreement for a further 6 months which will correspond to an extension and increase of the monthly fee.

Across the 12-month term, Vitrafy will provide two Guardion devices (previously named VCU2), access to LifeChain and service & support to successfully execute the pre-commercialisation activities.

The Agreement provides IMV exclusivity to Vitrafy's cryopreservation technology in the applications of assisted reproductive processes for farm animals and aquaculture for the term of the Agreement, with a specific carve out in place for Vitrafy's pre-existing commercial arrangements in aquaculture.

The initial 12-month term will run across calendar year 2026 with milestones throughout CY2026.

ENDS



This announcement is authorised by the Board of Vitrafy Life Sciences Limited.

For further information contact:

Investor and Media Relations

Simon Martin

Chief Financial Officer

investors@vitrafy.com

About Vitrafy Life Sciences Limited

Vitrafy Life Sciences Limited (ASX: VFY) has developed breakthrough cryopreservation technology that dramatically improves cell survival rates across multiple applications including blood platelets (>88% recovery vs >50% industry standard), cell & gene therapies (96% viability vs 70% industry minimum), aquaculture and bovine reproduction. The Company provides complete cryopreservation solutions through its managed service revenue model, utilising its FDA-registered Smart Freezing and Smart Thawing devices, integrated LifeChain™ software platform, and Smart Packaging systems.

For more information visit vitrafy.com.